Amyloidosis, Transthyretin Amyloid Cardiomyopathy | Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform
carDIo-ttranSSfOrm nucLEar Imaging Study
This is a multicenter trial of 80 subjects enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) who will undergo baseline and follow up Tc-99m PYP to assess for the change in myocardial uptake of the tracer.
Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform
Purpose of Study
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
Eligibility
Age:
60 - 90Sex:
AllKey Inclusion / Exclusion Criteria
Inclusion Criteria:
- Patients who were screened and eligible to be enrolled or have been already enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline 99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to screening for CARDIO-TTRansform.
- Patients have to meet the inclusion and exclusion criteria of CARDIO-TTRansform trial to be enrolled.
- Patient willing to consent for the study and undergo the study procedures.
Exclusion Criteria:
- None
Conditions:
Amyloidosis, Transthyretin Amyloid Cardiomyopathy
Status:
Recruiting
Phase:
Phase 3
Clinical Trials ID
NCT05259072
Read Detailed Summary:
Start Date / End Date:
01 2022 - 12 2026
Intervention:
Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform
Enrollment:
80